|Statement||chairman and editor, W. Rutishauser.|
|Contributions||Rutishauser, W. 1931-, European Congress of Cardiology (8th : 1980 : Paris, France)|
|LC Classifications||RC684V38 P53|
|The Physical Object|
|Pagination||99 p. :|
|Number of Pages||99|
In an attempt better to understand the pathophysiological mechanisms of chronic congestive heart failure as they apply to long-term treatment with vasodilators, the working group on vasodilator therapy of the Deutsche Gesellschaft fUr Herz- und Kreis laufforschung has assembled a group of physiologists, pharmacologists, and clinicians. Heart failure is a pathophysiological state in which cardiac output is insufficient to meet the needs of the body and lungs. The term "congestive heart failure" is often used, as one of the common symptoms is congestion, or build-up of fluid in a person's tissues and veins in the lungs or other parts of the body. Specifically, congestion takes the form of water retention and swelling (), Specialty: Cardiology. 1. Author(s): Rutishauser,Wilhelm; European Congress of Cardiology,(8th: Paris, France) Title(s): The Place of vasodilators in the long-term treatment of intractable heart failure: an international symposium held during the VIIIth European Congress of Cardiology, Paris / chairman and editor, W. Rutishauser. Abstract. Heart failure is a complex pathophysiologic disorder, which can be defined as the inability of the heart to pump blood at a rate commensurate with the ordinary metabolic demands of the organs and tissues in spite of sufficient venous : W. Rutishauser.
‘Heart failure’ is a term that may be loosely or precisely defined. The development of pulmonary oedema does not necessarily indicate a cardiac cause and of the cardiac causes for pulmonary oedema, not all can be attributed to left ventricular failure. 1 The majority of women developing symptoms and signs of heart failure during pregnancy have no known pre-existing Author: John Anthony, Karen Sliwa. Vasodilators are a heterogeneous group of drugs, with different modes and sites of actions. The common end result of their action is vasorelaxation and therefore a reduction in afterload, preload and, at the appropriate dose, blood lators can be classified on the basis of site of activity and presence or absence of additional cardiovascular pharmacologic properties ().Cited by: 6. Adults with congenital heart disease who underwent the Fontan operation to palliate single ventricle heart defects—by direct connection of caval venous return to the pulmonary circulation—have improved survival due to advancements in surgical and interventional techniques. However, cardiac and non-cardiac comorbidities often coexist, Cited by: 1. Recent health care reform efforts have focused on reducing day heart failure hospital readmissions, increasing the cost-effectiveness of care provided to .
Bradycardia is a slower than normal heart rate. The hearts of adults at rest usually beat between 60 and times a minute. If you have bradycardia (brad-e-KAHR-dee-uh), your heart beats fewer than 60 times a minute. Bradycardia can be a serious problem if the heart doesn't pump enough oxygen-rich blood to the body. The US has the highest maternal mortality rate in the developed world, at an estimated deaths per , live births. This rate is rising, although it is falling in other wealthy nations. 1 Cardiovascular disease is a leading cause of maternal death, so cardiologists need to build on their knowledge and enhance their proficiency on the management of Author: Nandita S Scott. Heart failure is a complex, true pandemic clinical syndrome and is responsible for 5% of hospitalizations globally. Severe heart failure can manifest as two lethal clinical entities: (1) acute cardiac decompensation with cardiogenic shock after large acute myocardial infarction with mortality rates approaching 50% or after cardiac surgery with mortality rates higher than 65% Cited by: 3. Long-term pharmacologic treatment of severe heart failure. As noted earlier, patients with heart failure should receive ACE inhibitors and beta-blockers if tolerated. Other vasodilators such as angiotensin receptor blockers or hydralazine/nitrate combinations can be used if the patient does not tolerate ACE inhibitors, for example, because of.